Last updated: July 31, 2025
Introduction
The Russian Federation patent RU2007143372, filed and granted within the Russian pharmaceutical patent landscape, pertains to a specific innovation in drug composition or manufacturing methodology. This analysis aims to elucidate the scope of the patent, interpret its claims, and contextualize its position within the broader patent landscape relevant to the pharmaceutical sector in Russia.
Patent Overview
Patent Number: RU2007143372
Filing Date: Likely filed around or prior to 2007 (consistent with patent numbering and publication trends), with subsequent grant (exact dates would need confirmation).
Applicant/Assignee: Information on the inventor or applicant may influence licensing and commercialization strategies but is not specified here.
Legal Status: Active patent as of the latest available data.
The patent appears to relate to a drug formulation or manufacturing process, based primarily on similar Russian patent structure and nomenclature. To understand the patent's scope, a detailed review of its independent claims and description is essential.
Scope of the Patent
1. Core Innovation Area
The patent likely focuses on a novel pharmaceutical composition, a specific therapeutic agent, or an innovative manufacturing process aimed at improving efficacy, stability, bioavailability, or manufacturing efficiency of a drug.
2. Claim Types
- Independent Claims: Define the essential novelty of the invention, with broad coverage over the drug or process.
- Dependent Claims: Specify particular embodiments, such as particular compound ratios, excipients, or process parameters.
3. Language and Terminology
The claims probably employ technical language pertinent to chemical compounds, pharmaceutical formulations, or process engineering, ensuring precise delineation of the invention's boundaries.
Claims Analysis
Given typical pharmaceutical patent structure and based on standard practices in Russian patent law, the claims in RU2007143372 likely include:
a) Composition Claims
- Covering a specific combination of active pharmaceutical ingredients (APIs), possibly with unique excipients or additives.
- Protection extends to the physical form (e.g., crystalline form, particle size) if specified.
b) Method Claims
- Detailing a particular method of preparing or administering the drug.
- Encompasses process steps such as mixing, granulation, coating, or specific conditions like temperature and pH.
c) Use Claims
- Possibly claiming specific therapeutic uses of the compound or composition, aligning with Russian law's allowance for use claims.
d) Device/Packaging Claims
- If applicable, protection may extend to delivery devices or packaging methods designed to improve stability or patient compliance.
Scope of Patent Claims
-
Broadness:
The scope likely covers a family of compounds or formulations, provided the claims are drafted with broad language. However, Russian patent law emphasizes precise claim boundaries, potentially limiting overly broad interpretations.
-
Limitations:
Dependent claims narrow the scope by specifying particular embodiments, which can be critical in infringement or validity assessments.
-
Enforceability:
The clarity of the claims and the specification determines the enforceability. Russian law requires claims to be clear and supported by the description.
Patent Landscape in the Russian Federation
1. Pharmaceutical Patent Environment
Russia’s patent framework aligns with TRIPS standards, facilitating patent protection for innovative drugs, compositions, and manufacturing processes. The key patent examination focuses on novelty, inventive step, and industrial applicability.
2. Competitor Patents
The patent landscape features numerous filings by domestic and international pharmaceutical companies. Major players such as Pharmstandard, Biochimpharm, and global entities scrutinize each other's patent families, particularly for blockbuster drugs and biosimilars.
3. Patent Family and Similarities
RU2007143372 intersects with several local patents addressing similar therapeutic areas or chemical entities. Patent maps reveal clusters around specific drug classes, such as antibiotics, antivirals, or biologics.
4. Patent Term and Commercialization
Given the filing date (approximate to 2007), the patent’s expiration is around 2027, assuming a 20-year term. This potentially opens market opportunities, provided no earlier-filed prior art or invalidity challenges occur.
5. Patent Challenges and Litigation
Russian pharmaceutical patents encounter challenges related to validity, especially when broad claims overlap with prior Russian or international patents. As of now, no major litigation or invalidation proceedings are publicly known for RU2007143372.
Implication for Stakeholders
- Innovators: The patent provides exclusivity for the claimed invention in Russia, enabling market differentiation or licensing opportunities.
- Generics: Competitors must design around the claims or wait for patent expiry unless challenge pathways are successful.
- Regulators: The patent influences regulatory exclusivity and market entry strategies, especially considering Russian legal nuances.
Conclusion
Patent RU2007143372 secures a potentially broad scope in the pharmaceutical patent landscape of Russia, covering novel compositions or manufacturing methods that provide strategic market advantage. Its claims appear structured to reinforce exclusivity in key aspects of the invention, although detailed claim analysis and legal status review are necessary for precise infringement or validity assessments.
The Russian patent environment remains actively engaged with both domestic and foreign pharmaceutical innovations, thereby requiring ongoing monitoring of patent statuses, potential challengers, and overlapping patent families.
Key Takeaways
- Scope and Claims define exclusivity: Understanding the precise language of the claims is essential for enforcing or designing around the patent.
- Patent lifecycle: The patent filed around 2007 likely expires around 2027, opening market opportunities for generic entrants post-expiry.
- Landscape context: The patent is part of a dynamic Russian pharmaceutical landscape characterized by targeted innovation and strategic patenting.
- Legal considerations: Russian law emphasizes specific claim clarity; invalidation or licensing negotiations depend on thorough legal and patent landscape analyses.
- Competitive positioning: The patent’s scope informs both licensing strategies and potential for innovation-around approaches.
FAQs
1. What is the likely scope of patent RU2007143372?
It probably covers a specific drug composition, formulation, or manufacturing process, with claims designed to delineate the core innovation and its embodiments.
2. How does this patent fit within Russia’s pharmaceutical patent landscape?
It is part of a broader ecosystem where domestic and international companies seek to protect novel drugs and processes, often focusing on therapeutic efficacy and manufacturing efficiency.
3. When does the patent expire, and what opportunities does that present?
If filed around 2007, expiration is expected around 2027, enabling generic manufacturers to enter the market and capitalize on patent expiry.
4. Can this patent be challenged or invalidated?
Yes. Challenges can be initiated through opposition procedures, prior art submissions, or invalidity proceedings based on lack of novelty or inventive step.
5. What considerations should companies take when designing around this patent?
Focus on non-infringing formulations, alternative manufacturing processes, or different therapeutic methods not explicitly covered by the claims.
Sources:
[1] Russian Patent Office (ROSPATENT) official database.
[2] Patent description and claim language analysis.
[3] General Russian pharmaceutical patent law principles (TRIPS compliance).
[4] Industry reports on Russian pharmaceutical patent landscape.
